Loading...
Navigating the new landscape of second‐line treatment in advanced hepatocellular carcinoma
Sorafenib and lenvatinib are approved for first‐line treatment of patients with advanced hepatocellular carcinoma (HCC), and the efficacy of atezolizumab plus bevacizumab has been demonstrated versus sorafenib. Over time, first‐line treatment frequently fails, and regorafenib, cabozantinib, ramuciru...
Saved in:
| Published in: | Liver Int |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
John Wiley and Sons Inc.
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7496898/ https://ncbi.nlm.nih.gov/pubmed/32432830 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/liv.14533 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|